Social Media Ideas for Drug Development

<![CDATA[How Basket-Trials are Reshaping Drug Development Timelines]]>

From Discovery to Development in Emerging Modalities

ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities a...

Illuminating the Drug Development Path with Cell-Based Reporter Assays

In early discovery, researchers use high-throughput screening (HTS) to identify active compounds in a biologically relevant context. During lead characterization and validation, th...

The hidden innovation system behind drug repurposing 

Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of research starts. The post The hidden innovation system be...

Success Stories: Accelerating Cancer Drug Discovery

As researchers work to develop new cancer treatments, one of the biggest challenges is identifying promising drug candidates quickly and efficiently. Now, researchers at Purdue Uni...

Biopharma moves to reduce development risk earlier than ever

Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.

Old Drugs, New Tricks: FDA’s Drug Repurposing Initiative

By Charles D. Snow & Kalie E. Richardson —

Critical Path Institute Unveils New Coalition to Propel Human-Relevant Drug Development Tools

TUCSON, Ariz., and AMSTERDAM — May 19, 2026 — In a transformative step for drug development and regulatory science, the Critical Path Institute (C-Path) has officially launched the...

AI Can Accelerate Discovery — Development Still Decides What Advances

AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions....

Leveraging Prior Knowledge – When Do Sponsors Not Have to Recreate the Wheel? Breaking Down FDA’s New Draft Guidance Fr...

By Mark A. Tobolowsky —

Next Generation Biopharma Innovation

In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies. The post Next Generation Biopharma Innovation appear...

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development

Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.

AACR D3: The ‘Global One-stop Conference’ for Drug Discovery and Development

The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology therapeutics. The post AACR D3: The ‘Global One-stop Conf...

<![CDATA[FDA Pilot Targets Faster Early-Stage Drug Trial Starts]]>

Planning a successful pivot from lab to clinic

For sterile injectables, key early decisions can have a significant impact on the products’ development.

Organ-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On It

Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA’s move away from reliance on animal testing towards or...

China Sets Framework for Advanced Therapeutic Development

China’s Order 818 signals the country’s intent to accelerate local innovation and standardize the drug development environment, thereby becoming a more important player in advanced...

China’s Rise in Drug Development Looms Over U.S.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the...

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

The in-depth, constantly-changing birds-eye view of disease that computational models provide is an essential next step in linking our ever-expanding clinical knowledge and data wi...

Novel Therapeutic Modalities Target the Undruggable

Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable a...

Developing a Drug To Reverse Heart Disease

We have spoken with Reason from Repair Biotechnologies about his company’s lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The...

Rethinking precision oncology drug development: AI and tumor biology for smarter therapeutic programs

Discover how precision oncology companies are using AI and patient-relevant biology to reduce clinical trial failures in cancer. The post Rethinking precision oncology drug develop...

<![CDATA[The Future for Disease Modifying Therapies for Lysosomal Disorders]]>

Brain-Targeted Drug Discovery Barriers Drive Deep Science Ventures and Medicines Discovery Catapult Deal

The partnership’s first phase will see a review of the current medicines landscape conducted to identify opportunities for innovation. This information will be used to find systemi...